Table 1: DAAs for hepatitis C [9,10,16,24,25,42,48].

DAA Class Approval Genotype Barrier to resistance Potency Combination (SVR)
Boceprevir NS3/4A PI 2011 1 Medium High RBV + IFN (SVR 61-75%)
Telaprevir NS3/4A PI 2011 1 Low High RBV + IFN (SVR 69-83%)
Simeprevir (SIM) NS3/4A PI 2013 1, 4 Low High with RBV + IFN (SVR79-86%)
or
with SOF (SVR 95-97%)
Asunaprevir (ASV) NS3/4A PI 2013 1b Medium High with DCV (SVR 82-90%)
Paritaprevir/r (PTV/r) NS3/4A PI
(ritonavir boosted)
2013 1, 4 Low High with OBV + DSV ± RBV
(SVR 90-99%)
Grazoprevir (GZR) NS3/4A PI 2016 1, 4 Low High with EBR (SVR 92-99%)
Sofosbuvir (SOF) NS5B 2013 Pangenotype High High

with RBV + IFN (SVR 89-90%)

or

with RBV (SVR 97% in GT2/3;

SVR 68-84% in GT1)

or

with SIM (SVR 95-97%)

or

with LDV (SVR 97-99%)

or

with VEL (SVR 95-99%)

or

with DCV (SVR 95-100%)

Dasabuvir (DSV) NS5B 2014 1 Low Low with OB + PTV/r ± RBV
(SVR 90-99%)
Ledipasvir (LDV) NS5A 2014 1, 4, 5 Low High with SOF (SVR 97-99%)
Ombitasvir (OBV) NS5A 2014 1, 4 Medium High with PTV/r plus DSV ± RBV
(SVR 90-99%)
Daclatasvir (DCV) NS5A 2014 Pangenotype Low High with SOF (SVR 91-100%)
Elbasvir (EBR) NS5A 2016 Pangenotype Medium High with GZR (SVR 92-99%)
Velpatasvir (VEL) NS5A 2016 Pangenotype Low High with SOF (SVR 97-99%)
Voxilaprevir (VOX) NS3/4A PI 2017 Pangenotype High High with SOF+VEL (SVR 97-99%)
Glecaprevir (GLE) NS3/4A PI 2017 Pangenotype High High With PIB (SVR 99%)
Pibrentasvir (PIB) NS5A 2017 Pangenotype High High With GLE (SVR 99%)